CORT, NCM

Corcept Therapeutics Incorporated (CORT)

Price (as of October 31)

28.44USD

Correlations

The correlation describes the statistical relationship between the value of two assets over time. Use this relationship to bet against an asset without shorting it or diversify your portfolio more effectively. Learn how you can use correlations to your advantage.

Lowest within Industry

Symbol Correlation

BTTX

Better Therapeutics, Inc.

-0.18

BOLT

Bolt Biotherapeutics, Inc.

-0.17

BWV

Blue Water Vaccines, Inc.

-0.12

CABA

Cabaletta Bio, Inc.

-0.1

RXRX

Recursion Pharmaceuticals, Inc.

-0.1

AMLX

Amylyx Pharmaceuticals, Inc.

-0.09

BCTX

BriaCell Therapeutics Corp.

-0.09

ADAG

Adagene Inc.

-0.08

AURA

Aura Biosciences, Inc.

-0.08

CGTX

Cognition Therapeutics, Inc.

-0.08

Show more

Highest within Industry

Symbol Correlation

BLTE

Belite Bio, Inc

0.16

ACHL

Achilles Therapeutics plc

0.1

APM

Aptorum Group Limited

0.08

AUTL

Autolus Therapeutics plc

0.07

ATHA

Athira Pharma, Inc.

0.06

AVTE

Aerovate Therapeutics, Inc.

0.06

ABSI

Absci Corporation

0.06

AKUS

Akouos, Inc.

0.05

ADTX

Aditxt, Inc.

0.05

ABVC

ABVC BioPharma, Inc.

0.05

Show more

Profile

Sector:
Healthcare
Industry:
Biotechnology

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing’s syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing’s syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.